SAN FRANCISCO--(BUSINESS WIRE)--Girard Gibbs LLP is investigating claims on behalf of users of Risperdal that the antipsychotic medication may be linked to the adverse side effect of gynecomastia, or male breast growth.
Hundreds of lawsuits have been filed alleging that Risperdal manufacturer Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, was aware of the risks associated with Risperdal use and intentionally concealed these risks from parents and consumers. The lawsuits allege that Risperdal causes irreversible breast growth in men and young boys that may be accompanied by lactation.
For the parents of one Risperdal user, the struggle to manage symptoms associated with autism was complicated by Risperdal’s allegedly undisclosed side effects. At age 8, their son had developed distinct breasts. Seeking treatment for the gynecomastia proved increasingly difficult as the child sought to hide the condition from others, including his parents and medical providers.
“We are talking about a group of people, many of whom are young boys, who are already suffering from the difficulties of behavioral and mental health concerns,” said Amy Zeman, a personal injury lawyer with Girard Gibbs working directly with Risperdal clients. “Our clients turn to Risperdal to help them, and instead end up in a situation where they are facing breast reduction surgery and an incredibly difficult social and emotional situation. I’ve spoken with mothers whose sons are too embarrassed to discuss it even with their closest family members.”
Consumers and parents of children affected by the use of Risperdal and generic risperidone are encouraged to contact Girard Gibbs’ Risperdal attorneys to learn more about the investigation and explore their potential claims for monetary compensation.
Girard Gibbs LLP has been distinguished by the U.S. News & World Report as a Tier-1 law firm for plaintiffs’ mass tort and class action litigation. In addition to representing people injured after taking Risperdal, Girard Gibbs represents plaintiffs involving Fresenius dialysate products GranuFlo and Naturalyte; Yaz, Yasmin, and Ocella birth control pills; the diabetes drug Actos; transvaginal mesh implants; Eon spinal cord stimulators; the DaVinci surgical robot; the Mirena IUD; and the blood-thinner Pradaxa.